The FDA decision on scPharmaceuticals Inc.’s (SCPH) Furoscix, proposed for the treatment of congestion in patients with worsening heart failure, is expected on October 8.Furoscix is a subcutaneous formulation of the approved diuretic furosemide delivered via a wearable, pre-programmed on-body drug delivery system, namely West Pharmaceutical Services Inc.’s SmartDoseGen II 10ml platform technology.This is the company’s third attempt to secure U.S. regulatory approval for Furoscix.The FDA had denied approval to Furoscix twice – in June 2018 and in December 2020.If approved, Furoscix has the potential to provide an outpatient therapeutic option to deliver IV-strength furosemide for the treatment of heart failure due to congestion, thereby avoiding the need for unnecessary, expensive hospitalizations which could improve patients’ quality of life with minimal interruption of daily living, according to the company.scPharma sees an addressable market opportunity of more than $5 billion for Furoscix in the U.S.SCPH closed Thursday’s (Sep.29,2022) trading at $6.05, up 3.95%.